General Biologicals Corporation (TPEX:4117)
Taiwan · Delayed Price · Currency is TWD 12.15
-0.15 (-1.22%)
Feb 11, 2026, 2:59 PM CST
General Biologicals Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 251.38 | 251.93 | 264.83 | 370.46 | 551.66 | 475.87 | |
Revenue Growth (YoY) | 3.70% | -4.87% | -28.51% | -32.85% | 15.93% | 98.57% |
Cost of Revenue | 242.71 | 244.39 | 202.12 | 198.61 | 269.72 | 224.81 |
Gross Profit | 8.67 | 7.54 | 62.71 | 171.85 | 281.94 | 251.06 |
Selling, General & Admin | 181.56 | 171.15 | 200.27 | 180.58 | 219.64 | 146.84 |
Research & Development | 47.58 | 49.53 | 36.25 | 35.85 | 34.25 | 41.13 |
Operating Expenses | 228.28 | 223.32 | 232.64 | 212.72 | 238.14 | 207.69 |
Operating Income | -219.61 | -215.78 | -169.94 | -40.87 | 43.79 | 43.37 |
Interest Expense | -24.41 | -13.37 | -11.98 | -16.86 | -11 | -3.32 |
Interest & Investment Income | 2.38 | 2.34 | 2.66 | 1.08 | 0.49 | 0.18 |
Earnings From Equity Investments | -0.04 | -0.25 | -6.93 | -1.34 | -0.16 | -3.04 |
Currency Exchange Gain (Loss) | -8.76 | 2.11 | -0.84 | 7.34 | -0.87 | -2.86 |
Other Non Operating Income (Expenses) | 3.23 | -0.22 | -5.58 | 4.38 | 2.41 | 11.97 |
EBT Excluding Unusual Items | -247.2 | -225.17 | -192.61 | -46.27 | 34.66 | 46.3 |
Gain (Loss) on Sale of Investments | 1.61 | 3.05 | 4.89 | 0.44 | -5.82 | 1.41 |
Gain (Loss) on Sale of Assets | - | - | - | -0.38 | 9.77 | 0.58 |
Other Unusual Items | - | - | - | 0.09 | - | - |
Pretax Income | -245.6 | -222.11 | -187.72 | -46.13 | 38.61 | 48.29 |
Income Tax Expense | -0.29 | -0.29 | 12.13 | 7.69 | -5.48 | -13.8 |
Earnings From Continuing Operations | -245.31 | -221.82 | -199.85 | -53.82 | 44.08 | 62.09 |
Minority Interest in Earnings | 1.71 | 1 | 1.01 | 0.63 | 0.06 | 0.06 |
Net Income | -243.6 | -220.82 | -198.83 | -53.19 | 44.14 | 62.15 |
Net Income to Common | -243.6 | -220.82 | -198.83 | -53.19 | 44.14 | 62.15 |
Net Income Growth | - | - | - | - | -28.98% | - |
Shares Outstanding (Basic) | 60 | 60 | 60 | 60 | 60 | 53 |
Shares Outstanding (Diluted) | 60 | 60 | 60 | 60 | 60 | 53 |
Shares Change (YoY) | - | - | - | -0.14% | 13.44% | 33.78% |
EPS (Basic) | -4.07 | -3.69 | -3.32 | -0.89 | 0.74 | 1.18 |
EPS (Diluted) | -4.07 | -3.69 | -3.32 | -0.89 | 0.74 | 1.18 |
EPS Growth | - | - | - | - | -37.38% | - |
Free Cash Flow | -642.94 | -1,661 | -198.33 | -23.42 | 24.24 | 23.49 |
Free Cash Flow Per Share | -10.75 | -27.77 | -3.31 | -0.39 | 0.41 | 0.45 |
Gross Margin | 3.45% | 2.99% | 23.68% | 46.39% | 51.11% | 52.76% |
Operating Margin | -87.36% | -85.65% | -64.17% | -11.03% | 7.94% | 9.11% |
Profit Margin | -96.90% | -87.65% | -75.08% | -14.36% | 8.00% | 13.06% |
Free Cash Flow Margin | -255.76% | -659.37% | -74.89% | -6.32% | 4.40% | 4.93% |
EBITDA | -182.84 | -195.25 | -150.37 | -22.69 | 64.95 | 63.47 |
EBITDA Margin | -72.73% | -77.50% | -56.78% | -6.12% | 11.77% | 13.34% |
D&A For EBITDA | 36.77 | 20.54 | 19.57 | 18.19 | 21.16 | 20.1 |
EBIT | -219.61 | -215.78 | -169.94 | -40.87 | 43.79 | 43.37 |
EBIT Margin | -87.36% | -85.65% | -64.17% | -11.03% | 7.94% | 9.11% |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.